Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients

Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients

The aim of this study is to evaluate the use of autologous expanded mesenchymal stem cells intralesional transplantation as a safe and potentially beneficial treatment for patients with spinal cord injury.

Inclusion Criteria:

• American Spinal Injury Association Impairment (ASIA) Scale A, B and C
• Cervical (under C4), thoracic o lumbar spine lesion
• Complete or Incomplete SCI
• Platelet count over 100.000/ul

Exclusion Criteria:

• Acute SCI (less than 3 months)
• Active infectious diseases
• Pregnancy
• Neurodegenerative diseases
• Primary hematologic diseases
• Coagulopathies
• Hepatic dysfunction
• Pregnancy